Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

Fineline Cube Feb 25, 2026
Company Deals

MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks

Fineline Cube Feb 25, 2026
Company Deals

Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor

Fineline Cube Feb 25, 2026
Company Deals

Dartsbio Licenses PACAP Antibody DS009 to Slate Medicines – $130M Series A Fuels Global Migraine Development

Fineline Cube Feb 25, 2026
Company Deals

Henlius Licenses Serplulimab to Abbott for Emerging Markets – Expands Anti‑PD‑1 Global Footprint

Fineline Cube Feb 25, 2026
Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Fineline Cube Feb 24, 2026
Company Drug

FDA Approves AstraZeneca’s Calquence Plus Venetoclax for CLL/SLL – First All‑Oral Fixed‑Duration Regimen

Fineline Cube Feb 25, 2026
Company Drug

Dupixent Wins FDA Approval for Allergic Fungal Rhinosinusitis – First Targeted Therapy for AFRS Expands Dupilumab Label

Fineline Cube Feb 25, 2026
Company Drug

HutchMed’s Orpathys Files for Expanded Indication in NSCLC Treatment in China

Fineline Cube Mar 28, 2024

HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that the National Medical Products Administration...

Company Drug

Astellas Pharma’s Padcev Combo Therapy Accepted for Review in China for Urothelial Carcinoma

Fineline Cube Mar 28, 2024

Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that China’s Center...

Policy / Regulatory

China Unveils Management Measures to Strengthen National Health Emergency Teams

Fineline Cube Mar 28, 2024

The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...

Hospital Policy / Regulatory

China’s NHC Mandates Enhanced Management and Accessibility of Midwifery Services

Fineline Cube Mar 28, 2024

The National Health Commission (NHC) has issued a notification with the aim of enhancing the...

Company Medical Device

AstraZeneca’s Tralokinumab Trial Data Spurs Development of Brainomix’s e-Lung Software

Fineline Cube Mar 28, 2024

AstraZeneca (AZ; NASDAQ: AZN) has reported data from a Phase II trial for its idiopathic...

Company Deals

BeiGene Terminates Partnership with Shoreline Therapeutics for NK Cell Therapies

Fineline Cube Mar 28, 2024

A close examination of BeiGene’s (NASDAQ: BGNE; HKG: 6160; SHA: 688235) recent annual report has...

Company

Luye Pharma Group Posts 2.7% YOY Revenue Growth in 2023 with Strong Market Performance

Fineline Cube Mar 28, 2024

Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced its...

Company

MicroPort CardioFlow Medtech Reports 33.9% YOY Revenue Growth in 2023 Financials

Fineline Cube Mar 28, 2024

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off from China-based MicroPort Scientific Corp (HKG:...

Company

Ascentage Pharma Reports 5.9% YOY Revenue Growth in 2023, Driven by Product Sales

Fineline Cube Mar 28, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has released its financial report...

Company

CanSino Biologics Reports 2023 Revenue Dip Amid Reduced COVID-19 Vaccine Demand

Fineline Cube Mar 28, 2024

CanSino Biologics (HKG: 6185), a leading Chinese biopharmaceutical company, has released its financial report for...

Company Deals

Recbio and Rongsheng Biotech Join Forces to Develop New Adjuvant Vaccine Technologies

Fineline Cube Mar 28, 2024

Jiangsu Recbio Technology Co., Ltd (HKG: 2179) and Shanghai Rongsheng Biotech Co., Ltd have announced...

Medical Device R&D

Tianjin University Team Develops Self-Sustaining Na-O2 Battery for Implantable Devices

Fineline Cube Mar 28, 2024

Researchers at China’s Tianjin University of Technology have made a groundbreaking advancement with the development...

Company Drug

Zai Lab and Novocure Report Positive Phase III Results for TTFields in NSCLC Brain Metastases

Fineline Cube Mar 28, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a biopharmaceutical company based in China, and Novocure...

Company Deals

Merck Expands Global Footprint with Largest M Lab Collaboration Center in Shanghai

Fineline Cube Mar 27, 2024

Merck KGaA (ETR: MRK), a leading German technology company, has announced the completion of the...

Company Deals

Kangtai Biological Partners with AstraZeneca and Beijing Daxing District to Boost Vaccine Market Presence

Fineline Cube Mar 27, 2024

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a prominent biopharmaceutical company based in China,...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for SHR-7631 ADC Clinical Study in Solid Tumors

Fineline Cube Mar 27, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

Wuhan YZY Biopharma Initiates Phase II Study for M701 in Malignant Pleural Effusion Treatment

Fineline Cube Mar 27, 2024

Wuhan YZY Biopharma Co., Ltd (HKG: 2496), a biopharmaceutical company based in China, has announced...

Company Medical Device

Acotec Scientific Receives NMPA Approval for Innovative Cardiovascular Devices

Fineline Cube Mar 27, 2024

Acotec Scientific Holdings Ltd (HKG: 6669), a leading medical device company based in China, has...

Company

Sanofi Launches KiDS Program in China to Boost Health Literacy in Schools

Fineline Cube Mar 27, 2024

Olivier Charmeil, Executive Vice-President for General Medicines at France-based Sanofi S.A. (NASDAQ: SNY), visited China...

Company

WuXi Bio Reports 2023 Revenue Growth Amid COVID-19 Business Loss and Geopolitical Tensions

Fineline Cube Mar 27, 2024

WuXi Bio (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...

Posts pagination

1 … 343 344 345 … 626

Recent updates

  • FDA Approves AstraZeneca’s Calquence Plus Venetoclax for CLL/SLL – First All‑Oral Fixed‑Duration Regimen
  • Dupixent Wins FDA Approval for Allergic Fungal Rhinosinusitis – First Targeted Therapy for AFRS Expands Dupilumab Label
  • United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential
  • Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer
  • Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

FDA Approves AstraZeneca’s Calquence Plus Venetoclax for CLL/SLL – First All‑Oral Fixed‑Duration Regimen

Company Drug

Dupixent Wins FDA Approval for Allergic Fungal Rhinosinusitis – First Targeted Therapy for AFRS Expands Dupilumab Label

Company Drug

United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential

Company Deals

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.